J Natl Cancer Inst 2005; 97: 425–432. 6 Powles T, Nelson M, Bower M. HIV-related testicular cancer. Int J STD AIDS 2003; 14: 24–27. 7 Wilson WT, Frenkel E, Vuitch F, Sagalowsky AI. Testicular tumors in men with human immunodeficiency virus. J Urol 1992; 147: 1038–1040. 8 Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus

Group (EGCCCG): part II. Eur Urol 2008; 53: 497–513. 9 Powles T, Imami N, Nelson M et al. Effects of combination selleck chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16: 531–536. 10 Hentrich M, Schiel X, Niedermeier A et al. Successful salvage high-dose chemotherapy and autologous stem-cell transplantation in HIV-related germ-cell tumor. Ann Oncol 2009; 20: 1900–1901. 11 Engels EA, Brock MV, Chen J et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24: 1383–1388. 12 Bower M, Powles T, Nelson M et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003; 17: 371–375. 13 D’Jaen GA, Pantanowitz L, Bower M et al. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral

therapy: a multi-institutional collaboration. Clin Lung Cancer 2010; 11: small molecule library screening 396–404. 14 Powles T, Nelson M, Bower M. HIV-related lung cancer – a growing concern? Int J STD AIDS 2003; 14: 647–651. 15 Vyzula R, Remick SC. Lung cancer in patients with HIV-infection. Lung Cancer 1996; 15: 325–339. 16 Sridhar KS, Flores MR, Raub WA Jr, Saldana M. Lung cancer in patients with human immunodeficiency

virus infection compared with historic control subjects. Chest 1992; 102: 1704–1708. 17 Powles T, Thirwell C, Newsom-Davis T et al. Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART? Br J Cancer 2003; 89: 457–459. 18 Hooker CM, Meguid RA, Hulbert A et al. Human immunodeficiency virus infection as a prognostic factor in surgical patients with non-small cell lung cancer. Ann Thorac Surg 2012; 93: 405–412. 19 Powles T, Powles J, Nelson M et al. Head and neck cancer in patients with human immunodeficiency virus-1 infection: incidence, outcome and Rucaparib solubility dmso association with Epstein-Barr virus. J Laryngol Otol 2004; 118: 207–212. 20 Pakkala S, Chen Z, Rimland D et al. Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer 2012; 118: 164–172. 21 Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–957. 22 Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.